![144005.jpg](http://contents.kyobobook.co.kr/sra/upload/book_img/144/144005.jpg)
Successful Management of Clozapine-induced Akathisia with Gabapentin Enacarbil: A Case Report
- 대한정신약물학회
- Clinical Psychopharmacology and Neuroscience
- Vol.16 No.3
- : SCOPUS, SCIE, KCI등재
- 2018.08
- 346 - 348 (3 pages)
The management of clozapine (CLZ)-induced adverse events affects patient prognoses. Akathisia is a relatively rare adverse event related to CLZ administration and thus the management of this syndrome is not well established. Here, we report a case of treatment-resistant schizophrenia wherein CLZ-induced akathisia was successfully managed with gabapentin enacarbil (GE). The patient was a 39-year-old woman who had been treated with atypical antipsychotics other than CLZ for three years with poor tolerability. Initiation of CLZ (400 mg/day) attenuated her psychotic symptoms, but was followed by moderate akathisia. Neither benzodiazepines nor biperiden improved the akathisia; however, akathisia was finally diminished with co-administration of GE. GE facilitated a dosage increase in CLZ (450 mg/day) for the improved management of pyschotic symptoms, and thus indirectly contributed to treatment of the patient’s schizophrenia. We suggest that GE is a useful candidate for the management of CLZ-induced akathisia. The improved management of treatment-induced akathisia and other adverse events can extend the potential application of CLZ for treatment-resistant schizophrenia.
INTRODUCTION
CASE
DISCUSSION